Business Wire

MI-EATON

8.9.2022 12:31:47 CEST | Business Wire | Press release

Share
Eaton to showcase innovative electrified commercial vehicle technologies at IAA Transportation show

Power management company Eaton will display technologies to support the zero emissions journey in the commercial vehicle market Sept. 20-25 at the IAA Transportation show in Hannover, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005014/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s eMobility business provides electrified vehicle solutions for its global commercial vehicle customers. (Photo: Business Wire)

“We are helping our customers around the globe with technologies that solve some of the toughest challenges throughout the electrified vehicle (EV) ecosystem,” said Scott Adams, president, Eaton’s eMobility business. “Eaton provides a vast portfolio of EV technologies for full battery electric, fuel cell and hybrid commercial vehicles, as well as EV charging infrastructure solutions.”

Flex Power Distribution Unit delivers safe power for commercial electrified vehicles

Eaton’s eMobility business offers a new Flex Power Distribution Unit (PDU) for high-voltage electrified commercial vehicles that is uniquely designed to handle multiple load requirements.

The Flex PDU integrates Eaton’s Breaktor® circuit protection technology, which improves vehicle safety and protects components from any level of overcurrent condition more effectively than traditional circuit protection methods. The Breaktor circuit protection solution is resettable like a circuit breaker, enabling reactivation of the device following a functionality check and reducing cost for both the OEM and consumer.

The Flex PDU also leverages sealed and corrosion-resistant terminals and connectors from Royal Power Solutions, a global leader in power distribution and transmission solutions that Eaton acquired earlier this year. Eaton’s Bussmann® series fuses are also integrated to meet the requirements for use in the latest high-powered electrified vehicles with ratings up to 1,000 volts of direct current (VDC) and 600 amps.

Eaton’s Flex PDU protects vital components and occupants and is also an intelligent unit that provides the OEM diagnostic information, including where the most power is being consumed, to maximize performance and efficiency. Its integrated and optimized design reduces the number of components, lessening complexity.

Electrified vehicle transmissions, gearing improves performance, range

Eaton’s new 4-speed transmissions provide superior performance on grades and acceleration for electrified commercial vehicles while offering more flexible gear ratios compared to competitive technologies. The compact 4-speed transmissions for medium- and heavy-duty electrified commercial vehicles also improve system efficiency, enabling longer vehicle range and battery life.

“We supply transmissions for multiple global commercial vehicle manufacturers, and many more are interested,” Adams said. “With decades of experience, we continue to build on our heritage as a top supplier of commercial vehicle transmissions.”

DC-DC converters available in a range of power configurations

Eaton recently introduced a 48-volt DC-DC converter to power accessories such as antilock brakes and lighting for commercial vehicles with 48-volt electrical systems. Unlike competitive offerings, Eaton’s DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.

Eaton’s DC-DC converter portfolio covers a spectrum of power requirements, ranging from low- to high-voltage systems, depending on customer specifications. The converters can be tuned for particular duty cycles via their advanced digital control architecture, enabling flexible control modes through firmware adaptation.

Green Motion acquisition bolsters Eaton’s vehicle charging capabilities

In March 2021, Eaton acquired Switzerland-based Green Motion SA, a leading designer and manufacturer of electric vehicle charging hardware and related software. Eaton’s efficient electric vehicle charging infrastructure expertise includes the production and operation of charging stations, designing management software for charging networks, and serving as an electric mobility service provider.

‘Buildings as a Grid’ strategy expands charging possibilities

Many workplaces host vehicle fleets, such as cars for the salesforce and vans for deliveries. Fleet managers switching to EVs, either now or in the future, will want to electrify their fleet while ensuring business continuity. Eaton’s “Buildings as a Grid” approach helps fleet managers devise an EV charging strategy that is fast to implement, cybersecure and scalable so that they can add more EV charging capacity when needed.

The strategy may include EV charging infrastructure at their site or depot, on-site renewables like solar panels on buildings, and options for fleet drivers to charge at home and when they are traveling. Eaton’s digital and physical infrastructure transforms a workplace or depot into an energy hub, and because it is a gateway to electrifying the entire functionality of the site, it is also an investment in the energy transition.

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, operate sustainably, and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for its stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005014/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye